Macroglobulinemia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MCR004 MIFTS: 49	Macroglobulinemia Categories: Cancer diseases, Immune diseases, Metabolic diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Macroglobulinemia

MalaCards integrated aliases for Macroglobulinemia:

Name: Macroglobulinemia ¹² ⁷⁴ ¹⁵ ¹⁷

Waldenstrom Macroglobulinemia ⁷¹

Primary Macroglobulinemia ¹²

Classifications:

MalaCards categories:
Global: Metabolic diseases Cancer diseases
Anatomical: Immune diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:9080

EFO ¹⁷ EFO_0002616

UMLS ⁷¹ C0024419

Sources

Summaries for Macroglobulinemia

MalaCards based summary : Macroglobulinemia, also known as waldenstrom macroglobulinemia, is related to waldenstroem's macroglobulinemia and lymphoplasmacytic lymphoma. An important gene associated with Macroglobulinemia is MYD88 (MYD88 Innate Immune Signal Transduction Adaptor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs rituximab and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, t cells and spleen, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : ⁷⁴ Macroglobulinemia is the presence of increased levels of macroglobulins in the circulating blood. It is... more...

Sources

Related Diseases for Macroglobulinemia

Diseases related to Macroglobulinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 523)

#	Related Disease	Score	Top Affiliating Genes
1	waldenstroem's macroglobulinemia	32.0	SDC1 PAX5 MYD88 HAS1 CXCR4 CD40LG
2	lymphoplasmacytic lymphoma	31.9	SDC1 PAX5 MYD88 CXCR4 CXCL12 CD40LG
3	monoclonal gammopathy of uncertain significance	31.9	SDC1 MYD88 IL6
4	cryoglobulinemia	31.2	TNFSF13B IL6 CD40LG
5	neutropenia	30.6	IL6 CXCR4 CD40LG AKT1
6	marginal zone b-cell lymphoma	30.6	SDC1 PAX5 MYD88 CD40LG BTK
7	plasmacytoma	30.5	PAX5 IL6 CXCL12 AKT1
8	anemia, autoimmune hemolytic	30.4	TNFSF13B CD52 CD40LG
9	exanthem	30.3	SYK IL6 AKT1
10	macular retinal edema	30.3	PRKCB IL6 CXCL12
11	monoclonal paraproteinemia	30.0	SDC1 PAX5
12	toxic shock syndrome	30.0	IL6 CD40LG CD40
13	leukemia, acute myeloid	30.0	SYK PAX5 IL6 CXCR4 CXCL12 BTK
14	trypanosomiasis	29.9	TNFRSF13C MYD88 IL6
15	plasma cell leukemia	29.9	SDC1 IL6 CD40
16	myelodysplastic syndrome	29.9	IL6 CXCR4 CXCL12 BTK AKT1
17	myeloma, multiple	29.8	TNFSF13B TNFRSF17 SDC1 MYD88 IL6 CXCR4
18	splenic marginal zone lymphoma	29.8	SYK SDC1 PAX5 CD40 BTK
19	b-cell lymphoma	29.8	TNFSF13B TNFRSF13C SYK PRKCB PAX5 MYD88
20	thrombocytopenia due to platelet alloimmunization	29.7	TNFSF13B TNFRSF13B SYK CD52
21	toxoplasmosis	29.7	MYD88 IL6 CD40LG CD40
22	agammaglobulinemia	29.7	TNFRSF13B SYK IL6 CXCR4 CD40LG CD40
23	burkitt lymphoma	29.7	TNFSF13B PAX5 IL6 CD40LG CD40
24	lymphoma, mucosa-associated lymphoid type	29.6	TNFSF13B TNFRSF13C SDC1 PAX5 MYD88 CD40
25	pneumocystosis	29.6	IL6 CD52 CD40LG BTK
26	primary agammaglobulinemia	29.5	TNFRSF13C TNFRSF13B SYK
27	central nervous system lymphoma	29.4	TNFSF13B PAX5 MYD88 IL6 CXCR4 CXCL12
28	diffuse large b-cell lymphoma	29.4	TNFSF13B SYK SDC1 PAX5 MYD88 IL6
29	mature b-cell neoplasm	29.3	SDC1 PAX5 IL6 CD40
30	cryptococcal meningitis	29.3	TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B
31	leukemia, acute lymphoblastic	29.3	SYK PAX5 CXCR4 CXCL12 CD40 BTK
32	mantle cell lymphoma	29.1	SYK PAX5 IL6 CXCR4 CD52 CD40LG
33	thrombocytopenia	29.1	TNFSF13B TNFRSF13C TNFRSF13B SYK PAX5 IL6
34	immunoglobulin alpha deficiency	29.0	TNFSF13B TNFRSF13C TNFRSF13B CD40LG CD40
35	combined immunodeficiency	28.8	IL6 CXCR4 CXCL12 CD70 CD40LG CD40
36	autoimmune disease	28.8	TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK IL6
37	lymphoma, non-hodgkin, familial	27.7	TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK SDC1
38	leukemia, chronic lymphocytic	27.5	TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK SDC1
39	macroglobulinemia, waldenstrom 1	11.5
40	macroglobulinemia, waldenstrom 2	11.2
41	schnitzler syndrome	11.1
42	light chain deposition disease	10.9
43	amyloidosis	10.6
44	lymphoproliferative syndrome	10.6
45	lymphoma	10.5
46	peripheral nervous system disease	10.5
47	neuropathy	10.5
48	splenomegaly	10.5
49	lymphoma, hodgkin, classic	10.4
50	polyneuropathy	10.3

Graphical network of the top 20 diseases related to Macroglobulinemia:

Sources

Symptoms & Phenotypes for Macroglobulinemia

GenomeRNAi Phenotypes related to Macroglobulinemia according to GeneCards Suite gene sharing:

²⁶ (show all 14)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	9.97	SDC1 SYK
2	Decreased viability	GR00055-A-2	9.97	SDC1 SYK
3	Decreased viability	GR00106-A-0	9.97	CD70 PAX5
4	Decreased viability	GR00154-A	9.97	BTK
5	Decreased viability	GR00221-A-1	9.97	AKT1 BTK PRKCB SYK
6	Decreased viability	GR00221-A-2	9.97	AKT1 BTK PRKCB SYK
7	Decreased viability	GR00221-A-3	9.97	AKT1 BTK SYK
8	Decreased viability	GR00221-A-4	9.97	AKT1 BTK PRKCB
9	Decreased viability	GR00240-S-1	9.97	CD40LG
10	Decreased viability	GR00249-S	9.97	AKT1 CD52 PRKCB SDC1 SYK TNFRSF13B
11	Decreased viability	GR00301-A	9.97	BTK
12	Decreased viability	GR00381-A-1	9.97	CXCR4 SDC1 TNFRSF13B
13	Decreased viability	GR00386-A-1	9.97	CD52 HAS1 PAX5 SYK
14	Decreased viability	GR00402-S-2	9.97	CD52 CXCR4 HAS1 PRKCB SDC1 STOML2

MGI Mouse Phenotypes related to Macroglobulinemia:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	hematopoietic system	MP:0005397	10.21	AKT1 BTK CD40 CD40LG CD70 CXCL12
2	homeostasis/metabolism	MP:0005376	10	AKT1 BTK CD40 CD40LG CXCR4 IL6
3	immune system	MP:0005387	9.93	AKT1 BTK CD40 CD40LG CD70 CXCL12
4	neoplasm	MP:0002006	9.23	AKT1 BTK CXCR4 IL6 MYD88 PAX5

Sources

Drugs & Therapeutics for Macroglobulinemia

Drugs for Macroglobulinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 242)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

rituximab

Approved

Phase 4

174722-31-7

10201696

Levoleucovorin

Approved, Investigational

Phase 4

68538-85-2

149436

Prednisolone acetate

Approved, Vet_approved

Phase 4

52-21-1

Prednisolone

Approved, Vet_approved

Phase 4

50-24-8

5755

Methylprednisolone hemisuccinate

Approved

Phase 4

2921-57-5

Methylprednisolone

Approved, Vet_approved

Phase 4

83-43-2

6741

Prednisolone phosphate

Approved, Vet_approved

Phase 4

302-25-0

Methotrexate

Approved

Phase 4

1959-05-2, 59-05-2

126941

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 4

59-30-3

6037

Prednisolone hemisuccinate

Experimental

Phase 4

2920-86-7

Antineoplastic Agents, Immunological

Phase 4

Immunosuppressive Agents

Phase 4

Anti-Inflammatory Agents

Phase 4

Hormones

Phase 4

Gastrointestinal Agents

Phase 4

Hormone Antagonists

Phase 4

Immunologic Factors

Phase 4

Dermatologic Agents

Phase 4

Antirheumatic Agents

Phase 4

Antineoplastic Agents, Hormonal

Phase 4

Immunoglobulins

Phase 4

glucocorticoids

Phase 4

Antibodies

Phase 4

Antiemetics

Phase 4

Immunoglobulins, Intravenous

Phase 4

Antimetabolites

Phase 4

Protective Agents

Phase 4

Methylprednisolone Acetate

Phase 4

Folic Acid Antagonists

Phase 4

Vitamin B Complex

Phase 4

Neuroprotective Agents

Phase 4

Vitamin B9

Phase 4

Folate

Phase 4

Vincristine

Approved, Investigational

Phase 3

2068-78-2, 57-22-7

5978

Doxorubicin

Approved, Investigational

Phase 3

23214-92-8

31703

Prednisone

Approved, Vet_approved

Phase 3

53-03-2

5865

Chlorambucil

Approved

Phase 3

305-03-3

2708

Antimitotic Agents

Phase 3

Tubulin Modulators

Phase 3

Liposomal doxorubicin

Phase 3

31703

BB 1101

Phase 3

HIV Protease Inhibitors

Phase 3

protease inhibitors

Phase 3

belimumab

Approved

Phase 2

356547-88-1

5957 10451420

Mesna

Approved, Investigational

Phase 2

3375-50-6

598

Cytarabine

Approved, Investigational

Phase 2

147-94-4

6253

Iodine

Approved, Investigational

Phase 2

7553-56-2

807

Erythromycin

Approved, Investigational, Vet_approved

Phase 2

114-07-8

12560

Pentostatin

Approved, Investigational

Phase 2

53910-25-1

40926 439693

Adenosine

Approved, Investigational

Phase 2

58-61-7

60961

Interventional clinical trials:

(show top 50) (show all 299)

#	Name	Status	NCT ID	Phase	Drugs
1	The Efficacy of Cyclophosphamide Plus Dexamethasone Combinated With Rituximab or Bortezomib for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Randomized Control Trial From China	Unknown status	NCT02844322	Phase 4	Bortezomib;Rituximab
2	The Efficacy of Thalidomide Plus Cyclophosphamide and Dexamethasone Following by Thalidomide and Prednisone Maintenance Therapy for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China	Unknown status	NCT02844309	Phase 4	Thalidomide
3	Autologous Stem-cell Transplantation Versus Conventional Chemotherapy for High Risk Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China	Unknown status	NCT02844361	Phase 4
4	Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO	Unknown status	NCT02378298	Phase 4	Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
5	A Single Arm, Multicenter, Phase 4 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) in Chinese Subjects With Relapse or Refractory Waldenström's Macroglobulinemia	Recruiting	NCT04042376	Phase 4	Ibrutinib
6	Randomized Trial Comparing the Efficacy of Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia,Lymphoplasmacytic Lymphoma or Splenic Marginal Zone Lymphoma	Completed	NCT00566332	Phase 3	Chlorambucil;Fludarabine
7	iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström's Macroglobulinemia	Completed	NCT02165397	Phase 3	Ibrutinib;Placebo;Rituximab
8	A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies	Completed	NCT00075478	Phase 3	Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
9	A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial	Completed	NCT01231412	Phase 3	Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
10	A Randomised Trial of Chlorambucil Versus Fludarabine as Initial Therapy of Waldenström's Macroglobulinaemia and Splenic Lymphoma With Villous Lymphocytes	Completed	NCT00608374	Phase 3	chlorambucil;fludarabine phosphate
11	First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.A Multicentre, Phase III Randomized Study by the PLRG.	Completed	NCT00801281	Phase 3	Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
12	Randomised Phase II/III Study of Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia	Recruiting	NCT04061512	Phase 2, Phase 3	Dexamethasone, cyclophosphamide, rituximab;Rituximab, ibrutinib
13	Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers	Recruiting	NCT02991638	Phase 3	Ibrutinib
14	Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia	Active, not recruiting	NCT01788020	Phase 3	Dexamethasone, Rituximab, Cyclophosphamide;Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
15	A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)	Active, not recruiting	NCT03053440	Phase 3	BGB-3111;Ibrutinib
16	A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study	Enrolling by invitation	NCT01804686	Phase 3	PCI-32765 (Ibrutinib)
17	Efficacy of Carfilzomib in Combination With Ibrutinib in Waldenström's Macroglobulinemia (CZAR-1)	Not yet recruiting	NCT04263480	Phase 3	Carfilzomib + Ibrutinib;Ibrutinib
18	Study of Safety, Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia	Unknown status	NCT02981745	Phase 1, Phase 2	CT-1530
19	A Phase 2 Study to Evaluate the Efficacy of Bortezomib in Patients With De-novo Waldenstrom's Macroglobulinemia and Lymphoplasmacytic Lymphoma	Unknown status	NCT03335098	Phase 2	Bortezomib
20	Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia: A Multicenter Trial of the European Myeloma Network	Unknown status	NCT01046006	Phase 2	Bortezomib, Rituximab, Dexamethasone
21	Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Waldenstrom's Macroglobulinemia	Unknown status	NCT00041379	Phase 1, Phase 2	beta alethine
22	Velcade/Dexamethasone/Cyclophosphamide(PCD) Versus Rituximab /Dexamethasone/Cyclophosphamide(RCD) for the Treatment of Patients With Waldenstrom's Macroglobulinemia	Unknown status	NCT02971982	Phase 1, Phase 2	rituximab /Dexamethasone/cyclophosphamide;Velcade/Dexamethasone/cyclophosphamide
23	A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531	Unknown status	NCT01813227	Phase 2	Carfilzomib;Rituximab;Dexamethasone
24	A Single Arm, Phase II Study of the Anti-Blys Monoclonal Antibody, Belimumab in Symptomatic Waldenstroms Macroglobulinaemia	Unknown status	NCT01142011	Phase 2	Belimumab
25	A Phase 1b/2 Investigator Initiated Study of RCHOP in Combination With Selinexor (KPT-330) in B Cell Non-Hodgkin's Lymphoma	Unknown status	NCT03147885	Phase 1, Phase 2	Selinexor
26	Phase II Trial of LBH589 (Panobinostat) in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia	Completed	NCT00936611	Phase 2	LBH589
27	Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies	Completed	NCT01416428	Phase 1, Phase 2	oprozomib
28	A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia	Completed	NCT02302469	Phase 1, Phase 2	Revlimid
29	A Phase IIA Trial Testing the Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia	Completed	NCT00777738	Phase 2	BORTEZOMIB
30	UARK 99-006, A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia	Completed	NCT00083707	Phase 2	Thalidomide
31	Phase II Study of Combination Bortezomib (Velcade PS-341) and Rituximab in Patients With Previously Untreated and Relapsed/Refractory Waldenstrom's Macroglobulinemia	Completed	NCT00422799	Phase 2	Bortezomib;Rituximab
32	A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia	Completed	NCT00422656	Phase 2	Perifosine
33	A Phase II Study of the Combination Bortezomib (Velcade, PS-341), Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia	Completed	NCT00250926	Phase 2	Bortezomib;Dexamethasone;Rituximab
34	Phase II Study of Sildenafil Citrate in Waldenstrom's Macroglobulinemia	Completed	NCT00165295	Phase 2	Sildenafil citrate (Viagra)
35	Phase II Study of Velcade in Waldenstrom's Macroglobulinemia	Completed	NCT00142129	Phase 2	Bortezomib (Velcade)
36	Phase II Study of Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia	Completed	NCT00142116	Phase 2	Thalidomide;Rituximab
37	Carfilzomib, Rituximab, and Dexamethasone (CaRD) in Waldenstrom's Macroglobulinemia	Completed	NCT01470196	Phase 2	Dexamethasone;Carfilzomib;Rituximab
38	An Open Label, Multicenter Phase 2 Study of Single-Agent Enzastaurin HCl in Previously Treated Waldenstrom's Macroglobulinemia or Multiple Myeloma	Completed	NCT00718419	Phase 2	Enzastaurin
39	Phase II Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia	Completed	NCT02400437	Phase 2	Ixazomib;Dexamethasone;Rituximab
40	Fase II Study With Bortezomib, Rituximab and Bendamustin-BRB- for Non-Hodgkin Lymphoplasmocytic Lymphoma/Waldenstrom Macroglobulinemia's Patients at First Relapse	Completed	NCT02371148	Phase 2	Bortezomib-Rituximab-Bendamustine
41	An Extension Study to Evaluate the Long-Term Safety, Tolerability, and Clinical Activity of IMO-8400 in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia Who Completed Study 8400-401	Completed	NCT02363439	Phase 1, Phase 2	IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly
42	Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia	Completed	NCT01614821	Phase 2	PCI-32765
43	Phase II Study of Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia	Completed	NCT00976248	Phase 2	RAD001
44	Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstroms Macroglobulinemia: A Multicenter Trial of the European Myeloma Network	Completed	NCT00832234	Phase 2	Bortezomib, Dexamethasone, Rituximab
45	Phase I/II Study of G3139 (Genasense) in Patients With Waldenstrom's Macroglobulinemia	Completed	NCT00062244	Phase 1, Phase 2
46	Phase II Study of Campath-1H in Patients With Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia)	Completed	NCT00142181	Phase 2	Campath-1H
47	A Phase II Study Of PS-341 (NSC 681239) In Patients With Untreated Or Relapsed Waldenstrom's Macroglobulinemia	Completed	NCT00045695	Phase 2	bortezomib
48	Phase II Study of Rituximab (Rituxan, Mabthera) in Waldenstrom's Macroglobulinemia	Completed	NCT00004889	Phase 2
49	S9805, Phase II Study of Tandem High Dose Melphalan Supported by Peripheral Blood Stem Cell Support in Waldenstrom's Macroglobulinemia (WM)	Completed	NCT00003416	Phase 2	dexamethasone;melphalan
50	Phase II Study of Combination Rituxan (Rituximab, Mabthera) and Fludarabine Therapy in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia)	Completed	NCT00020800	Phase 2	fludarabine phosphate

Search NIH Clinical Center for Macroglobulinemia

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵¹ :

Chlorambucil

Cyclophosphamide

Ibrutinib

Thalidomide

Sources

Genetic Tests for Macroglobulinemia

Sources

Anatomical Context for Macroglobulinemia

MalaCards organs/tissues related to Macroglobulinemia:

⁴⁰

Bone Marrow, T Cells, Spleen, Myeloid, B Cells, Skin, Kidney

Sources

Publications for Macroglobulinemia

Articles related to Macroglobulinemia:

(show top 50) (show all 3450)

#	Title	Authors	PMID	Year
1	Bruton Tyrosine Kinase Inhibitors in Waldenstrom Macroglobulinemia: Unprecedented Clinical Activity and Promising Future Directions. ⁶¹	Owen RG	33444081	2021
2	Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. ⁶¹	Gertz MA	33368476	2021
3	Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. ⁶¹	Gunaratne MDSK...Paludo J	33054437	2021
4	Pre-analytical mysteries: A case of severe hypervitaminosis D and mild hypercalcaemia. ⁶¹	Whittle E...Morton A	33380896	2021
5	Multimodal imaging of two cases of retinal vein occlusion secondary to Waldenstrom macroglobulinemia. ⁶¹	Remoli Sargues L...Cervera Taulet E	33535793	2021
6	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. ⁶¹	Treon SP...Castillo JJ	32931398	2021
7	Cryoglobulinemic glomerulonephritis with underlying occult HBV infection and Waldenström macroglobulinemia: A case report. ⁶¹	Chuang YC...Kuo TH	33607837	2021
8	Clinical application of genomics in Waldenström macroglobulinemia. ⁶¹	Branagan AR...Castillo JJ	33569985	2021
9	Solitary renal mass in Waldenström macroglobulinemia. ⁶¹	Hamill M...Quinn J	33560218	2021
10	Mast cells (MC) excess in a bone marrow (BM) associated with lymphoplasmacytic cells (LPC) in a 55-Y-old patient with Waldenström's macroglobulinemia (WM). ⁶¹	Gentelet M...Demulder A	33527905	2021
11	Real-world treatment patterns and outcomes in a national study of Veterans with Waldenström macroglobulinemia, 2006-2019. ⁶¹	Chien HC...Halwani A	33606890	2021
12	CXCR4 in Waldenström's Macroglobulinema: chances and challenges. ⁶¹	Kaiser LM...Buske C	33273682	2021
13	What the Silent Retina Tells You: Serous Retinal Detachment in Waldenström's Macroglobulinemia. ⁶¹	Amaador K...Vos J	33490879	2021
14	Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of Waldenström macroglobulinemia in two cases. ⁶¹	Vergneault H...Royer B	33596645	2021
15	Severe and Irreversible Pancytopenia Associated With SARS-CoV-2 Bone Marrow Infection in a Patient With Waldenstrom Macroglobulinemia. ⁶¹	Velier M...Venton G	33563581	2021
16	Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition. ⁶¹	Matissek SJ...Elsawa SF	33356554	2021
17	Inducible skin-associated lymphoid tissue (iSALT) in a patient with Schnitzler syndrome who manifested wheals on recurrent localized erythema. ⁶¹	Kamido H...Kabashima K	33445206	2021
18	Tractional Retinal Detachment in a Patient With Waldenström's Macroglobulinemia. ⁶¹	Tsiogka A...Petrou P	33542877	2021
19	Hyperviscosity Syndrome in Rheumatoid Arthritis. ⁶¹	Miller JB...Baer AN	33452169	2021
20	Hematological disorder associated Cxcr4-gain-of-function mutation leads to uncontrolled extrafollicular immune response. ⁶¹	Alouche N...Espeli M	33512437	2021
21	Management of Waldenström macroglobulinemia in 2020. ⁶¹	Castillo JJ...Treon SP	33275726	2020
22	Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas. ⁶¹	Wagner-Johnston ND...Gopal AK	33300385	2020
23	Proximal Nerve Root Involvement in immunoglobulin M Anti-Myelin-Associated Glycoprotein Neuropathy Presenting as Cauda Equina Syndrome. ⁶¹	Fernandes M...Santos L	33214398	2020
24	Optical coherence tomography angiography characteristics in Waldenström macroglobulinemia retinopathy: A case report. ⁶¹	Li J...Sun P	33344607	2020
25	Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies. ⁶¹	Varettoni M...Arcaini L	32780514	2020
26	[Clinical characteristics and prognosis of Waldenström's macroglobulinemia: a clinical data report from a single center]. ⁶¹	Jia YC...Du J	33445850	2020
27	Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. ⁶¹	Dimopoulos M...Tam CS	33284944	2020
28	Emerging drugs for the treatment of Waldenström macroglobulinemia. ⁶¹	Despina F...Efstathios K	32955949	2020
29	Predictors of short-term survival in Waldenström Macroglobulinemia. ⁶¹	Ruan G...Kapoor P	32662697	2020
30	Zanubrutinib for the treatment of Waldenström Macroglobulinemia. ⁶¹	Lim KJC...Tam CS	33297772	2020
31	Bing-Neel syndrome: A case reports. ⁶¹	Demircioglu S...Ceneli O	33356992	2020
32	Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey. ⁶¹	Gocer M...Kurtoglu E	33303706	2020
33	The Eyes Cannot See What the Mind Does Not Know: Endocrinological Side Effects of Ibrutinib. ⁶¹	Chandrashekar N...McKenney R	33428844	2020
34	Waldenström Macroglobulinemia of the orbit: A diagnostic challenge. ⁶¹	Adiga S...Rastogi P	33183084	2020
35	A prognostic index predicting survival in transformed Waldenström macroglobulinemia. ⁶¹	Durot E...Castillo JJ	33179472	2020
36	Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma. ⁶¹	Hatcher JM...Gray NS	33214835	2020
37	Chronic lymphoproliferative disorders and secondary cancers in the era of purine analogues and beyond. ⁶¹	Harrop S...Tam CS	33222561	2020
38	Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm. ⁶¹	Shekhar R...Malhotra P	33217360	2020
39	Halting the FGF/FGFR axis leads to anti-tumor activity in Waldenström's Macroglobulinemia by silencing MYD88. ⁶¹	Sacco A...Roccaro AM	33197938	2020
40	Diagnosis of a difficult to differentiate case of early-onset hyperviscosity syndrome caused by IgM type multiple myeloma: a case report. ⁶¹	Yoshimura T...Yamane T	32572827	2020
41	Rheumatic involvement and bone scan features in Schnitzler syndrome: initial and follow-up data from a single-center cohort of 25 patients. ⁶¹	Darrieutort-Laffite C...Neel A	33208192	2020
42	CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies. ⁶¹	Le Cann M...Roos-Weil D	32959046	2020
43	Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis. ⁶¹	Ntanasis-Stathopoulos I...Dimopoulos MA	32723621	2020
44	[Watch out for a second train]. ⁶¹	Bravetti C...Degaud M	33026348	2020
45	Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia. ⁶¹	Madamsetty VS...Chanan-Khan A	32558607	2020
46	Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis. ⁶¹	Parrondo RD...Murthy HS	32616401	2020
47	Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. ⁶¹	Trotman J...Tam CS	32698195	2020
48	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. ⁶¹	Tam CS...Dimopoulos M	32731259	2020
49	A promising new therapy of oral Ixazomib without rituximab for Waldenstrom's Macroglobulinemia. ⁶¹	Ma W...Zhang L	33121225	2020
50	Bing-Neel syndrome revealing Waldenström's macroglobulinemia: a case report. ⁶¹	Jennane S...Doghmi K	33479948	2020

Sources

Genes for Macroglobulinemia

Genes related to Macroglobulinemia (0 elite genes):

(show all 23)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	MYD88	MYD88 Innate Immune Signal Transduction Adaptor	Protein Coding	34.02	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
2	CXCR4	C-X-C Motif Chemokine Receptor 4	Protein Coding	23.84	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications (show sections)
3	BTK	Bruton Tyrosine Kinase	Protein Coding	15.22	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	STOML2	Stomatin Like 2	Protein Coding	15.03	GeneCards inferred via : Publications Proteins (show sections)
5	SDC1	Syndecan 1	Protein Coding	13.28	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	TNFSF13B	TNF Superfamily Member 13b	Protein Coding	13.13	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	CD40LG	CD40 Ligand	Protein Coding	12.85	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	IL6	Interleukin 6	Protein Coding	12.83	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	CXCL12	C-X-C Motif Chemokine Ligand 12	Protein Coding	12.7	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	SYK	Spleen Associated Tyrosine Kinase	Protein Coding	12.57	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	12.54	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	PAX5	Paired Box 5	Protein Coding	12.51	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	HAS1	Hyaluronan Synthase 1	Protein Coding	12.44	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	PRKCB	Protein Kinase C Beta	Protein Coding	12.31	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	TNFRSF17	TNF Receptor Superfamily Member 17	Protein Coding	12.23	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	TNFRSF13B	TNF Receptor Superfamily Member 13B	Protein Coding	12.19	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	CD70	CD70 Molecule	Protein Coding	12.16	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	CD52	CD52 Molecule	Protein Coding	12.14	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	TNFRSF13C	TNF Receptor Superfamily Member 13C	Protein Coding	12.13	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	CD40	CD40 Molecule	Protein Coding	12	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	TP53	Tumor Protein P53	Protein Coding	11.98	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
22	CD27	CD27 Molecule	Protein Coding	11.98	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
23	BLNK	B Cell Linker	Protein Coding	11.91	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Macroglobulinemia

Sources

Expression for Macroglobulinemia

Search GEO for disease gene expression data for Macroglobulinemia.

Sources

Pathways for Macroglobulinemia

Pathways related to Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 48)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁵ Show member pathways Immune System ⁶⁵ Neutrophil degranulation ⁶⁵	14.01	TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK PRKCB
2	ERK Signaling ⁶³ Show member pathways ILK Signaling ⁶³ MAPK Signaling ⁶³ Molecular Mechanisms of Cancer ⁶³ Rho Family GTPases ⁶³	13.82	TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B PRKCB IL6
3	PEDF Induced Signaling ⁶³ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶³ Cytokine-cytokine receptor interaction ³⁶ Endothelin-1 Signaling Pathway ⁶³ Glucocorticoid Receptor Signaling ⁶³ IL-6 Pathway ⁶³ MIF Mediated Glucocorticoid Regulation ⁶³ MIF Regulation of Innate Immune Cells ⁶³ NFAT Signaling and Lymphocyte Interactions ⁶³ PGC1Alpha Pathway ⁶³ RAR-Gamma-RXR-Alpha Degradation ⁶³ STAT3 Pathway ⁶³	13.68	TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B PRKCB IL6
4	TGF-Beta Pathway ⁶³ Show member pathways JAK-STAT Pathway ⁶³ JNK Pathway ⁶³ MAPK Family Pathway ⁶³ Regulation of eIF4 and p70S6K ⁶³ SOCS Pathway ⁶³	13.52	TNFSF13B TNFRSF17 TNFRSF13C IL6 CXCR4 CXCL12
5	Cytokine Signaling in Immune system ⁶⁵ Show member pathways Signaling by Interleukins ⁶⁵	13.36	TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK MYD88
6	Akt Signaling ⁶³ Show member pathways p38 Signaling ⁶³ Tec Kinases Signaling ⁶³	13.18	TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK PRKCB
7	PAK Pathway ⁶³ Show member pathways Antioxidant Action of Vitamin-C ⁶³ Epithelial Adherens Junctions ⁶³	13.14	TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B PRKCB IL6
8	Phospholipase-C Pathway ⁶³ Show member pathways PTEN Pathway ⁶³	13.05	SYK PRKCB IL6 CXCL12 BTK AKT1
9	Toll-like Receptor Signaling Pathway ³⁶ ¹ Show member pathways Chagas disease ³⁶ Hepatitis B ³⁶ Hepatitis C ³⁶ Regulation of toll-like receptor signaling pathway ¹	13.05	SYK PRKCB MYD88 IL6 CD40 BTK
10	Human cytomegalovirus infection ³⁶ Show member pathways Human immunodeficiency virus 1 infection ³⁶ Kaposi sarcoma-associated herpesvirus infection ³⁶	12.93	SYK PRKCB MYD88 IL6 CXCR4 CXCL12
11	Allograft rejection ³⁶ ¹ Show member pathways Antigen processing and presentation ³⁶ Asthma ³⁶ Autoimmune thyroid disease ³⁶ CTL Mediated Apoptosis ⁶³ Graft-versus-host disease ³⁶ Intestinal immune network for IgA production ³⁶ THC Differentiation Pathway ⁶³ Type I diabetes mellitus ³⁶ Viral myocarditis ³⁶	12.85	TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B IL6 CXCR4
12	Pathways in cancer ³⁶	12.82	PRKCB IL6 CXCR4 CXCL12 AKT1
13	Development Angiotensin activation of ERK ²³ Show member pathways Cell adhesion Integrin inside-out signaling ²³ Development ACM2 and ACM4 activation of ERK ²³ Development Angiotensin signaling via PYK2 ²³ Development EDNRB signaling ²³ Development EPO-induced MAPK pathway ²³ Development G-Proteins mediated regulation MARK-ERK signaling ²³ Signal transduction IP3 signaling ²³	12.82	SYK CXCR4 CXCL12 BTK AKT1
14	Measles ³⁶ Show member pathways Epstein-Barr virus infection ³⁶ Influenza A ³⁶	12.82	SYK PRKCB MYD88 IL6 CD40 BTK
15	NF-KappaB Family Pathway ⁶³ Show member pathways NF-KappaB (p50-p65) Pathway ⁶³	12.71	TNFSF13B TNFRSF13C PRKCB MYD88 IL6 CXCL12
16	4-1BB Pathway ⁶³ Show member pathways CD27 Pathway ⁶³ CD40 Signaling ⁶³ CMV and MAPK Pathways ⁶³ NF-KappaB Activation by EBV ⁶³ NF-kappaB Activation by Viruses ⁶³ PKR Pathway ⁶³ SUMO Pathway ⁶³ TNFR2 Pathway ⁶³	12.66	PRKCB CXCR4 CD70 CD40LG CD40 AKT1
17	Immune response NFAT in immune response ²³ Show member pathways Immune response CD28 signaling ²³ Immune response ICOS pathway in T-helper cell ²³ Immune response T cell receptor signaling pathway ²³	12.62	SYK CD40LG CD40 BTK AKT1
18	TRAF Pathway ⁶³ Show member pathways 14-3-3 Induced Apoptosis ⁶³ TNF Superfamily Pathway ⁶³ Toll-Like Receptors Pathway ⁶³	12.59	TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B MYD88 CD70
19	NF-kappaB Signaling ⁴	12.54	TNFSF13B TNFRSF17 SYK PAX5 MYD88 CXCR4
20	B Cell Receptor Signaling Pathway (sino) ⁶⁶ Show member pathways B Cell Receptor Signaling Pathway ⁶⁶	12.45	SYK PRKCB CD40 BTK AKT1
21	RANK Signaling in Osteoclasts ⁶³ Show member pathways Apoptosis and survival APRIL and BAFF signaling ²³ APRIL Pathway ⁶³ BAFF in B-Cell Signaling ⁶³ RANK Pathway ⁶³ RANKL/RANK (Receptor activator of NFKB (ligand)) Signaling Pathway ¹	12.43	TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK AKT1
22	JAK-STAT signaling pathway ³⁶ Show member pathways B-Cell Development ⁶³ IL-7 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types ⁶⁴ Interleukin-19, 20, 22, 24 ⁶⁵ Jak/STAT Signaling Pathway ⁶⁴ Type III interferon signaling ¹	12.39	IL6 CXCR4 CXCL12 AKT1
23	ICos-ICosL Pathway in T-Helper Cell ⁶³ Show member pathways Calcium Mediated T-Cell Apoptosis ⁶³ CD28 Signaling in T-Helper Cell ⁶³	12.39	SYK PRKCB CD40LG CD40 AKT1
24	B cell receptor signaling pathway (KEGG) ³⁶ Show member pathways B Cell Receptor Signaling Pathway ¹ BCR signaling pathway ¹	12.38	SYK PRKCB BTK AKT1
25	Human T-cell leukemia virus 1 infection ³⁶	12.32	TNFRSF13C IL6 CD40 AKT1
26	Toll Comparative Pathway ⁶³ Show member pathways IL-1 Pathway ⁶³ Immune response MIF in innate immunity response ²³ iNOS Signaling ⁶³ TLR-TRIF Pathway ⁶³	12.29	SDC1 MYD88 IL6 AKT1
27	Toxoplasmosis ³⁶ Show member pathways Leishmaniasis ³⁶	12.27	PRKCB MYD88 CD40LG CD40 AKT1
28	Tuberculosis ³⁶	12.22	SYK MYD88 IL6 AKT1
29	C-type lectin receptor signaling pathway ³⁶ Show member pathways Pathogen or Damage-activated C-Type Lectin Receptor Signaling Pathways ⁶⁴	12.21	SYK MYD88 IL6 BTK AKT1
30	Kit receptor signaling pathway ¹ Show member pathways IL-3 Signaling Pathway ¹ Signaling events mediated by Stem cell factor receptor (c-Kit) ¹	12.16	SYK PRKCB BTK AKT1
31	IL-2 Signaling Pathway ¹ Show member pathways IL2-mediated signaling events ¹ IL-5 Signaling Pathway ¹	12.07	SYK PRKCB BTK AKT1
32	AGE-RAGE signaling pathway in diabetic complications ³⁶	11.88	PRKCB IL6 AKT1
33	Fc gamma R-mediated phagocytosis ³⁶	11.86	SYK PRKCB AKT1
34	Rheumatoid arthritis ³⁶	11.84	TNFSF13B IL6 CXCL12
35	Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway ²³ Show member pathways Apoptosis and survival Anti-apoptotic TNFs/NF-kB/IAP pathway ²³	11.81	TNFSF13B TNFRSF17 TNFRSF13B CD40LG CD40
36	TNF Superfamily Pathway: Human Ligand-Receptor Interactions and their Associated Functions ⁶⁴ Show member pathways TNFs bind their physiological receptors ⁶⁵	11.78	TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B CD70 CD40LG
37	CXCR4-mediated signaling events ¹	11.74	CXCR4 CXCL12 AKT1
38	AGE/RAGE pathway ¹	11.67	PRKCB MYD88 AKT1
39	HIF-1-alpha transcription factor network ¹	11.66	CXCR4 CXCL12 AKT1
40	Malaria ³⁶	11.59	SDC1 MYD88 IL6 CD40LG CD40
41	Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway ¹	11.5	IL6 BTK AKT1
42	Primary immunodeficiency ³⁶	11.45	TNFRSF13C TNFRSF13B CD40LG CD40 BTK
43	African trypanosomiasis ³⁶	11.39	PRKCB MYD88 IL6
44	IgA-Producing B Cells in the Intestine ⁶⁴	11.38	TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B PAX5 IL6
45	Syndecan-4-mediated signaling events ¹	11.3	TNFRSF13B CXCR4 CXCL12
46	NF-kappa B signaling pathway ³⁶	11.29	TNFSF13B TNFRSF13C SYK PRKCB MYD88 CXCL12
47	CD40/CD40L signaling ¹	11.28	CD40LG CD40 AKT1
48	G-protein signaling_Rap2B regulation pathway ²³	11.02	TNFSF13B IL6 CXCL12 CD70 CD40LG BTK

Sources

GO Terms for Macroglobulinemia

Cellular components related to Macroglobulinemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	membrane	GO:0016020	10.06	TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK STOML2
2	plasma membrane	GO:0005886	9.58	TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK STOML2
3	external side of plasma membrane	GO:0009897	9.43	TNFRSF13C SDC1 CXCR4 CXCL12 CD40LG CD40

Biological processes related to Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 33)

#	Name	GO ID	Score	Top Affiliating Genes
1	signal transduction	GO:0007165	10.13	TNFSF13B TNFRSF17 PRKCB MYD88 IL6 CXCR4
2	immune response	GO:0006955	9.99	TNFSF13B IL6 CXCR4 CXCL12 CD70 CD40LG
3	adaptive immune response	GO:0002250	9.95	TNFRSF17 TNFRSF13C TNFRSF13B SYK PRKCB BTK
4	immune system process	GO:0002376	9.91	TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B SYK PRKCB
5	inflammatory response	GO:0006954	9.87	SDC1 MYD88 IL6 CXCR4 CD40LG CD40
6	positive regulation of interleukin-6 production	GO:0032755	9.83	SYK MYD88 IL6
7	positive regulation of tumor necrosis factor production	GO:0032760	9.82	SYK MYD88 IL6
8	response to organic substance	GO:0010033	9.82	SDC1 BTK AKT1
9	cellular response to mechanical stimulus	GO:0071260	9.8	MYD88 CD40 AKT1
10	cellular calcium ion homeostasis	GO:0006874	9.8	STOML2 PRKCB CXCL12 CD40
11	positive regulation of smooth muscle cell proliferation	GO:0048661	9.78	MYD88 IL6 AKT1
12	positive regulation of interleukin-8 production	GO:0032757	9.77	SYK MYD88 IL6
13	platelet activation	GO:0030168	9.77	SYK PRKCB IL6 CD40LG CD40
14	positive regulation of interleukin-12 production	GO:0032735	9.74	SYK CD40LG CD40
15	positive regulation of B cell proliferation	GO:0030890	9.73	TNFSF13B TNFRSF13C CD40
16	positive regulation of interleukin-10 production	GO:0032733	9.72	SYK IL6 CD40LG
17	B cell activation	GO:0042113	9.71	PRKCB CD40 BTK
18	T cell costimulation	GO:0031295	9.71	TNFSF13B TNFRSF13C CD40LG AKT1
19	B cell proliferation	GO:0042100	9.7	CD70 CD40LG CD40
20	detection of mechanical stimulus involved in sensory perception of pain	GO:0050966	9.66	CXCR4 CXCL12
21	positive regulation of B cell differentiation	GO:0045579	9.65	SYK BTK
22	cellular response to oxidised low-density lipoprotein particle stimulus	GO:0140052	9.64	MYD88 AKT1
23	positive regulation of mitochondrial membrane potential	GO:0010918	9.63	STOML2 AKT1
24	positive regulation of NF-kappaB transcription factor activity	GO:0051092	9.63	PRKCB MYD88 IL6 CD40LG CD40 BTK
25	CD40 signaling pathway	GO:0023035	9.62	CD40LG CD40
26	regulation of immunoglobulin production	GO:0002637	9.62	CD40LG CD40
27	response to peptidoglycan	GO:0032494	9.61	MYD88 IL6
28	telencephalon cell migration	GO:0022029	9.59	CXCR4 CXCL12
29	cellular response to molecule of fungal origin	GO:0071226	9.58	SYK BTK
30	B cell costimulation	GO:0031296	9.58	TNFSF13B TNFRSF13C
31	response to ultrasound	GO:1990478	9.46	CXCR4 CXCL12
32	positive regulation of T cell proliferation	GO:0042102	9.35	TNFSF13B TNFRSF13C IL6 CD70 CD40LG
33	tumor necrosis factor-mediated signaling pathway	GO:0033209	9.17	TNFSF13B TNFRSF17 TNFRSF13C TNFRSF13B CD70 CD40LG

Molecular functions related to Macroglobulinemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	signaling receptor activity	GO:0038023	9.62	TNFRSF17 TNFRSF13C TNFRSF13B CD40
2	cytokine activity	GO:0005125	9.35	TNFSF13B IL6 CXCL12 CD70 CD40LG
3	tumor necrosis factor receptor binding	GO:0005164	9.33	TNFSF13B CD70 CD40LG
4	Toll-like receptor binding	GO:0035325	9.26	SYK MYD88
5	signaling receptor binding	GO:0005102	9.1	TNFSF13B SYK STOML2 MYD88 CXCL12 CD70

Sources

Sources for Macroglobulinemia

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Mar-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia

Macroglobulinemia

Aliases & Classifications for Macroglobulinemia

MalaCards integrated aliases for Macroglobulinemia:

Classifications:

External Ids:

Summaries for Macroglobulinemia

Related Diseases for Macroglobulinemia

Diseases related to Macroglobulinemia via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Macroglobulinemia:

Symptoms & Phenotypes for Macroglobulinemia

GenomeRNAi Phenotypes related to Macroglobulinemia according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Macroglobulinemia:

Drugs & Therapeutics for Macroglobulinemia

Drugs for Macroglobulinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 71 / NDF-RT 51 :

Genetic Tests for Macroglobulinemia

Anatomical Context for Macroglobulinemia

MalaCards organs/tissues related to Macroglobulinemia:

Publications for Macroglobulinemia

Articles related to Macroglobulinemia:

Genes for Macroglobulinemia

Genes related to Macroglobulinemia (0 elite genes):

Variations for Macroglobulinemia

Expression for Macroglobulinemia

Pathways for Macroglobulinemia

Pathways related to Macroglobulinemia according to GeneCards Suite gene sharing:

GO Terms for Macroglobulinemia

Cellular components related to Macroglobulinemia according to GeneCards Suite gene sharing:

Biological processes related to Macroglobulinemia according to GeneCards Suite gene sharing:

Molecular functions related to Macroglobulinemia according to GeneCards Suite gene sharing:

Sources for Macroglobulinemia

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵¹ :